Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies
纤维化发病机制和解决:从机制到治疗
基本信息
- 批准号:10678808
- 负责人:
- 金额:$ 0.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-15 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAccelerationAddressAgingAlberta provinceAreaAutomobile DrivingBiological MarkersBiological ProcessBiotechnologyCanadaCareer MobilityCessation of lifeChronicCicatrixClinicalClinical TrialsCollaborationsDevelopmentDiagnosisDiseaseEducationEducational workshopEpigenetic ProcessEventFibroblastsFibrosisFosteringGrowthHealth Care CostsHealthcare SystemsHeterogeneityHumanIndustryInfectious AgentInjuryInstitutionJointsKnowledgeLearningLinkLiver FibrosisMetabolicMethodologyMolecularNatural regenerationOncogenicOrganOrgan failureOutcomeParticipantPathogenesisPharmaceutical PreparationsPharmacologic SubstancePhysiciansPopulationResearchResearch PersonnelResolutionSafetyScientistSpeedSymptomsTechnologyTherapeuticTissuesTranslatingTranslationsTraumaVirus DiseasesWorkantifibrotic treatmentbench to bedsidecareerclinical practicecostdesigndrug discoveryhealingimprovedmultidisciplinarynext generationnon-alcoholic fatty liver diseasenonalcoholic steatohepatitisnovelnovel strategiespostersresponsesymposiumtissue repair
项目摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Fibrosis Pathogenesis and Resolution:
From Mechanisms to Therapies, organized by Drs. David Lagares, Boris Hinz and Carine Boustany. The
conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023.
Human fibrotic diseases are characterized by progressive tissue scarring in response to overwhelming or
chronic injury, ultimately leading to organ failure and death. Fibrotic diseases cause healthcare costs reaching
$10 billion per year. These costs are expected to further increase with our aging populations, our increasing
capacity to diagnose fibrotic disorders and the emergence of novel infectious agents such as SARS-CoV-2,
which can promote the development of fibrosis. Therefore, this conference was designed to identify common
and distinct mechanisms driving fibrosis in response to different insults (e.g., viral infection, trauma, oncogenic
injury). This conference will also address the following emerging themes in the field: 1) the mechanisms which
amplify and perpetuate tissue fibrosis, such as aging, epigenetics, and mechanobiology, 2) the relevance of
fibroblast heterogeneity in tissue repair and fibrosis, and 3) understanding the mechanisms promoting fibrosis
resolution and regeneration to devise novel strategies to truly regenerate fibrotic organs. This forum will also
focus on major clinical challenges including the lack of robust fibrosis biomarkers, safety endpoints, and clinical
trial endpoints. Advances in these areas will break down barriers in translating anti-fibrotic therapies from
bench to bedside. This Keystone Symposia conference will accelerate fibrosis research and anti-fibrotic drug
discovery by fostering interdisciplinary interactions among a diverse group of physicians and scientists from
both academic institutions and the pharmaceutical and biotech industry. Finally, this conference will be held
jointly with Metabolic and Molecular Mechanisms of NAFLD/NASH. The joint conference will highlight current
evidence linking key biological processes involved in NASH and liver fibrosis. Participants from both
conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster
sessions.
抽象的
请求支持Keystone研讨会会议,标题为“纤维化发病机理和分辨率:
从机制到疗法,由Drs组织。大卫·拉加雷斯(David Lagares),鲍里斯·欣兹(Boris Hinz)和卡琳·博斯塔尼(Carine Boustany)。这
会议将于2023年3月19日至23日在加拿大艾伯塔省的班夫举行。
人类纤维化疾病的特征是响应压倒性或
慢性伤害,最终导致器官衰竭和死亡。纤维化疾病导致医疗保健费用达到
每年100亿美元。期望这些成本随着我们的老龄化而进一步增加
诊断纤维化疾病的能力以及新型感染剂(例如SARS-COV-2)的出现
可以促进纤维化的发展。因此,该会议旨在确定常见
以及驱动纤维化的不同机制,以响应不同的损伤(例如病毒感染,创伤,致癌性)
受伤)。该会议还将解决该领域中以下新兴主题:1)机制
扩增和永久性组织纤维化,例如衰老,表观遗传学和机械生物学,2)
组织修复和纤维化中的成纤维细胞异质性,以及3)了解促进纤维化的机制
解决和再生,以设计新型策略来真正再生纤维化器官。这个论坛也将
专注于主要的临床挑战,包括缺乏可靠的纤维化生物标志物,安全终点和临床
试验终点。这些领域的进步将打破障碍物在翻译抗纤维化疗法方面
长凳到床边。这次Keystone研讨会会议将加速纤维化研究和抗纤维化药物
通过在各种各样的医师和科学家之间培养跨学科互动来发现
学术机构以及制药和生物技术行业。最后,这次会议将举行
与NAFLD/NASH的代谢和分子机制联合。联合会议将突出显示当前
与NASH和肝纤维化有关的关键生物过程联系的证据。两者的参与者
会议将有机会通过共享的会议,进餐时间和晚间海报进行联网
会议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TERRY L. SHEPPARD其他文献
TERRY L. SHEPPARD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TERRY L. SHEPPARD', 18)}}的其他基金
Pulmonary Hypertension: State of the Art and Therapeutic Opportunities
肺动脉高压:最新技术和治疗机会
- 批准号:
10682118 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Infections in Pregnancy: PathogenicMechanisms, Experimental Advances and Clinical Strategies
妊娠期感染:致病机制、实验进展和临床策略
- 批准号:
10540260 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Mechanisms of Microbiota-Immune Interactions-Towards the Next Decade
微生物群-免疫相互作用的机制-迈向下一个十年
- 批准号:
10753451 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Transposable Elements at the Crossroads of Evolution, Health and Disease
处于进化、健康和疾病十字路口的转座元件
- 批准号:
10750852 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Long COVID and Post Acute Sequalae of SARS CoV 2 (PASC): Pathogenesis and Treatment
长期新冠肺炎和 SARS CoV 2 (PASC) 急性后遗症:发病机制和治疗
- 批准号:
10749522 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
B Cell Biology in the Context of Infectious Diseases, Autoimmunity and B Cell Cancers
传染病、自身免疫和 B 细胞癌症背景下的 B 细胞生物学
- 批准号:
10683443 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Inflammation in the Lung: Friend or Foe in Viral Infections?
肺部炎症:病毒感染的朋友还是敌人?
- 批准号:
10681956 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
相似国自然基金
基于腔光机械效应的石墨烯光纤加速度计研究
- 批准号:62305039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于自持相干放大的高精度微腔光力加速度计研究
- 批准号:52305621
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
位移、加速度双控式自复位支撑-高层钢框架结构的抗震设计方法及韧性评估研究
- 批准号:52308484
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
高离心加速度行星排滚针轴承多场耦合特性与保持架断裂失效机理研究
- 批准号:52305047
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于偏心光纤包层光栅的矢量振动加速度传感技术研究
- 批准号:62305269
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
IAS 2023, the 12th IAS Conference on HIV Science, Brisbane, Australia, and virtually, 23-26 July 2023
IAS 2023,第 12 届 IAS HIV 科学会议,澳大利亚布里斯班,虚拟会议,2023 年 7 月 23-26 日
- 批准号:
10696505 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Neuroprotective Potential of Vaccination Against SARS-CoV-2 in Nonhuman Primates
SARS-CoV-2 疫苗对非人灵长类动物的神经保护潜力
- 批准号:
10646617 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
NeuroMAP Phase II - Recruitment and Assessment Core
NeuroMAP 第二阶段 - 招募和评估核心
- 批准号:
10711136 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Investigating the role and therapeutic potential of the alpha5beta1 integrin in risk factors for COVID-19-associated cognitive impairment
研究 α5β1 整合素在 COVID-19 相关认知障碍危险因素中的作用和治疗潜力
- 批准号:
10658178 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别:
Impact of obesity on SARS-CoV-2 infection and reciprocal effects of SARS-CoV-2 on metabolic disease
肥胖对 SARS-COV-2 感染的影响以及 SARS-COV-2 对代谢疾病的相互影响
- 批准号:
10583175 - 财政年份:2023
- 资助金额:
$ 0.5万 - 项目类别: